Shareholder Alert: The Ademi Firm investigates whether Akero Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

, /PRNewswire/ -- The Ademi Firm is investigating Akero (NASDAQ: AKRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Nordisk. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of Akero will receive $54.00 per share, representing an equity value of approximately $4.7 billion. Shareholders will also receive a c ...